Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes. - Elsaid MI; Li N; Firkins SA; Rustgi VK; Paskett ED; Acharya C; Reddy KR; Chiang CW; Mumtaz K (Alimentary pharmacology & therapeutics, 2024)